Geographic and temporal trends in antimicrobial nonsusceptibility in Streptococcus pneumoniae in the post-vaccine era in the United States.

BACKGROUND We examined whether observed increases in antibiotic nonsusceptible nonvaccine serotypes after introduction of pneumococcal conjugate vaccine in the United States in 2000 were driven primarily by vaccine or antibiotic use. METHODS  Using active surveillance data, we evaluated geographic and temporal differences in serotype distribution and within-serotype differences during 2000-2009. We compared nonsusceptibility to penicillin and erythromycin by geography after standardizing differences across time, place, and serotype by regressing standardized versus crude proportions. A regression slope (RS) approaching zero indicates greater importance of the standardizing factor. RESULTS  Through 2000-2006, geographic differences in nonsusceptibility were better explained by within-serotype prevalence of nonsusceptibility (RS 0.32, 95% confidence interval [CI], .08-.55 for penicillin) than by geographic differences in serotype distribution (RS 0.71, 95% CI, .44-.97). From 2007-2009, serotype distribution differences became more important for penicillin (within-serotype RS 0.52, 95% CI, .11-.93; serotype distribution RS 0.57, 95% CI, .14-1.0). CONCLUSIONS  Differential nonsusceptibility, within individual serotypes, accounts for most geographic variation in nonsusceptibility, suggesting selective pressure from antibiotic use, rather than differences in serotype distribution, mainly determines nonsusceptibility patterns. Recent trends suggest geographic differences in serotype distribution may be affecting the prevalence of nonsusceptibility, possibly due to decreases in the number of nonsusceptible serotypes.

[1]  M. Lipsitch,et al.  Niche and Neutral Effects of Acquired Immunity Permit Coexistence of Pneumococcal Serotypes , 2012, Science.

[2]  W. Schaffner,et al.  Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. , 2012, The Journal of infectious diseases.

[3]  M. Lipsitch,et al.  Serotype replacement in disease after pneumococcal vaccination , 2011, The Lancet.

[4]  M. Haber,et al.  Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  W. Schaffner,et al.  Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Matthew R Moore,et al.  A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination. , 2010, Vaccine.

[7]  R. Lynfield,et al.  Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. , 2010, The Journal of infectious diseases.

[8]  W. Schaffner,et al.  Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. , 2010, The Journal of infectious diseases.

[9]  Marc Lipsitch,et al.  What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae? , 2009, Journal of The Royal Society Interface.

[10]  D. Greenberg,et al.  The Association Between Antibiotic Use in the Community and Nasopharyngeal Carriage of Antibiotic-Resistant Streptococcus pneumoniae in Bedouin Children , 2008, The Pediatric infectious disease journal.

[11]  W. Schaffner,et al.  Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. , 2008, The Journal of infectious diseases.

[12]  A. Shefer,et al.  Trends in Acute Otitis Media-Related Health Care Utilization by Privately Insured Young Children in the United States, 1997–2004 , 2008, Pediatrics.

[13]  Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005. , 2008, MMWR. Morbidity and mortality weekly report.

[14]  Clinical,et al.  Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement , 2008 .

[15]  P. Paakkari,et al.  Macrolide and Azithromycin Use Are Linked to Increased Macrolide Resistance in Streptococcus pneumoniae , 2006, Antimicrobial Agents and Chemotherapy.

[16]  W. Schaffner,et al.  Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. , 2006, The New England journal of medicine.

[17]  F. Baquero,et al.  Geographical and Ecological Analysis of Resistance, Coresistance, and Coupled Resistance to Antimicrobials in Respiratory Pathogenic Bacteria in Spain , 2005, Antimicrobial Agents and Chemotherapy.

[18]  M. Jacobs,et al.  Macrolide resistance: an increasing concern for treatment failure in children , 2003, The Pediatric infectious disease journal.

[19]  Marc Lipsitch,et al.  Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States , 2003, Nature Medicine.

[20]  E. Lewis,et al.  Impact of the pneumococcal conjugate vaccine on otitis media , 2003, The Pediatric infectious disease journal.

[21]  F. Baquero,et al.  Importance of Local Variations in Antibiotic Consumption and Geographical Differences of Erythromycin and Penicillin Resistance in Streptococcus pneumoniae , 2002, Journal of Clinical Microbiology.

[22]  Susan R. Johnson,et al.  Macrolide Resistance among Invasive Streptococcus Pneumoniae Isolates , 2022 .

[23]  R. Dagan,et al.  Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees , 2001, The Pediatric infectious disease journal.

[24]  M. Lipsitch,et al.  Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  L. Harrison,et al.  Active bacterial core surveillance of the emerging infections program network. , 2001, Emerging infectious diseases.

[26]  M. Cetron,et al.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. , 2000, The New England journal of medicine.

[27]  G. Doern,et al.  Antimicrobial-drug use and changes in resistance in Streptococcus pneumoniae. , 2000, Emerging infectious diseases.

[28]  Paterick Bd,et al.  Geographic Variation in Penicillin Resistance in Streptococcus pneumoniae: Selected Sites, United States, 1997. , 2000, Annals of emergency medicine.

[29]  Paterick Bd,et al.  Geographic variation in penicillin resistance in Streptococcus pneumoniae--selected sites, United States, 1997. , 1999, MMWR. Morbidity and mortality weekly report.